Dr. Lee Je-hwan Hematology

Consultant - Hematologist , Experience:

Book Appointment

About Doctor

Dr. Lee Je-hwan is among the best doctor for treatment of leukemia and blood related disorders in Seoul, South Korea.

Dr. Lee Je-hwan education
  • Doctor of Medicine : Chungbuk National University
  • Master of Medicine : University of Ulsan
  • Bachelor of Medicine : Seoul National University
Dr. Lee Je-hwan major professional experiences
  • Professor in Hematology, UUCM AMC
  • Associate Professor in Hematology, UUCM AMC
  • Assistant Professor in HematoOncology, UUCM AMC
  • Clinical Instructor in HematoOncology, UUCM AMC
  • Fellowship in HematoOncology, UUCM AMC
  • Residency in Internal Medicine, UUCM AMC
  • Internship in Seoul National University Hospital


Asan Medical Centre, Seoul, South Korea


Procedures Performed

Research & Publications

Prognostic impact of lymphocyte subpopulations in peripheral blood after hematopoietic stem cell transplantation for hematologic malignancies.
The detailed kinetics of cytomegalovirus-specific T cell responses after hematopoietic stem cell transplantation: 1 year follow-up data.
Allogeneic hematopoietic cell transplantation for lymphoma: baseline and posttransplant prognostic factors.
Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study.
Clinical characteristics and outcomes of patients with chronic disseminated candidiasis who need adjuvant corticosteroid therapy.
Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort.
Epidemiology and Risk Factors for Invasive Fungal Diseases among Allogeneic Hematopoietic Stem Cell Transplant Recipients in Korea: Results of “RISK” Study.
Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.
Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome.
Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy